Laden…
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propionic acid
Levodopa is a dopamine precursor that is converted to dopamine in the brain and is primarily used to treat Parkinson's disease. It increases dopaminergic activity and can improve motor symptoms. The substance works by increasing dopamine levels but also affects other neurochemical systems. Side effects may include motor fluctuations and dyskinesias.
Translation in progress
The German version has more complete content. This English page is being expanded; safety-critical risk and interaction sections may still appear while translation continues.
Receptor Targets
Mechanism of Action
Designations
IUPAC: (2S)-2-amino-3-(3,4-dihydroxyphenyl)propionic acid
Synapedia Evidence
Effects & Pharmacology translation in progress
English prose is being expanded. The German version currently has more detail.
Total duration 4-6 hours
Peak
1-2 hours
Onset
30-60 minutes
Total duration
4-6 hours
After effects
2-4 hours
Start low. Individual sensitivity varies.
Dose sensitivity varies greatly between individuals. Body weight, tolerance, route of administration, combinations, and pre-existing conditions significantly affect outcomes. These figures are not dosing recommendations — they describe reported ranges, not safe amounts.
Risks
Summary
Mögliche Nebenwirkungen umfassen Übelkeit, Schwindel und Bewegungsstörungen.
Safer Use
The risks listed may be incomplete. Especially for research chemicals and rare substances, available data is limited.
Interaction details from the knowledge layer are still being translated.
Interaction data is based on known mechanisms. Unknown or rare interactions are possible and may be life-threatening.
This information is for scientific and harm-reduction purposes only. It does not constitute medical advice.
Share a report, observation, or question about this substance. Entries are reviewed before publication and marked as unverified community signals.
These entries are submitted by users and are not verified. They may contain subjective experiences, observations, source leads, or corrections. They do not replace scientific data and are not consumption advice.
The signal hub collects approved risk signals, experience reports and source leads by relevance.